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Abstract
Background: The incidence of colorectal cancer (CRC) is increasing in developing countries, yet limited research on
the CRC- associated microbiota has been conducted in these areas, in part due to scarce resources, facilities, and
the difficulty of fresh or frozen stool storage/transport. Here, we aimed (1) to establish a broad representation of
diverse developing countries (Argentina, Chile, India, and Vietnam); (2) to validate a ‘resource-light’ sample-
collection protocol translatable in these settings using guaiac faecal occult blood test (gFOBT) cards stored and,
importantly, shipped internationally at room temperature; (3) to perform initial profiling of the collective CRC-
associated microbiome of these developing countries; and (4) to compare this quantitatively with established CRC
biomarkers from developed countries.
Methods: We assessed the effect of international storage and transport at room temperature by replicating gFOBT
from five UK volunteers, storing two in the UK, and sending replicates to institutes in the four countries. Next, to
determine the effect of prolonged UK storage, DNA extraction replicates for a subset of samples were performed
up to 252 days apart. To profile the CRC-associated microbiome of developing countries, gFOBT were collected
from 41 treatment-naïve CRC patients and 40 non-CRC controls from across the four institutes, and V4 16S rRNA
gene sequencing was performed. Finally, we constructed a random forest (RF) model that was trained and tested
against existing datasets from developed countries.
Results: The microbiome was stably assayed when samples were stored/transported at room temperature and after
prolonged UK storage. Large-scale microbiome structure was separated by country and continent, with a smaller
effect from CRC. Importantly, the RF model performed similarly to models trained using external datasets and
identified similar taxa of importance (Parvimonas, Peptostreptococcus, Fusobacterium, Alistipes, and Escherichia).
Conclusions: This study demonstrates that gFOBT, stored and transported at room temperature, represents a
suitable method of faecal sample collection for amplicon-based microbiome biomarkers in developing countries
and suggests a CRC-faecal microbiome association that is consistent between developed and developing countries.
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Background
Colorectal cancer (CRC) is the fourth commonest cause
of global cancer-related deaths. Incidence rates have
traditionally been highest in developed countries, but are
increasing in developing countries, many of which are
ill-equipped to respond to this new burden of disease
[1]. There is growing evidence of an association between
CRC and an altered faecal microbiome, with the poten-
tial to develop novel screening, prognostic or therapeutic
markers. Certain bacteria have been proposed as puta-
tive oncomicrobes and specific genetic elements such as
toxins have been implicated [2]. However, the majority
of CRC-microbiome research has profiled developed co-
horts. Of the limited number of studies conducted in de-
veloping countries, most have been small pilot studies
[3–7]. It cannot be assumed that results from developed
countries will be generalisable to developing populations,
as the health-associated microbiome of developed and
developing populations has been shown to differ taxo-
nomically and functionally [8].
One of the biggest limitations to conducting micro-
biome research in developing countries is storage and
transport of frozen stool, which is widely considered the
gold standard. Alternative methods have been proposed,
and include storing faeces on screening cards (Flinders
Technology Associates (FTA) cards or guaiac faecal oc-
cult blood test (gFOBT) CRC screening cards) at room
temperature [9–15]. Two studies have indicated that
cards could be used to store stool at high ambient tem-
peratures, such as those of many developing countries
[16, 17]. However, these studies did not assess the effect
of international transport on microbiome stability. Many
microbiome studies use samples collected on site or
transported frozen, severely limiting protocol options in
developing countries. Other protocols have been ex-
plored for collection, storage, and transport at ambient
temperatures for gut microbiome studies in developing
nations, including gFOBT card variants. However, this
still requires thorough testing and optimisation for clin-
ical use, particularly as this is not the equivalent of stor-
age in temperature-controlled settings (transport
temperatures are likely to be highly variable, encompass-
ing transport at outside-temperature to the airport,
transport within the cargo of an aeroplane and transit
times of ~weeks).
To improve the field’s ability to conduct low-cost gut
microbiome profiling for CRC screening in developing
countries, and to provide a pilot assessment of the global
CRC-linked microbiome, we established a network com-
prising researchers from the continents of South Amer-
ica (Argentina and Chile, Development Assistance
Committee (DAC)-listed upper-middle income countries
at the time of the study), South East Asia (India and
Vietnam, DAC-listed lower-middle income countries),
and Europe (UK) as a control. These countries represent
a range of increasing CRC incidence rates (Age Standar-
dised World Rate in 2018 per 100,000 person-years:
India 4.4; Vietnam 13.4; Chile 20.7; Argentina 25.0; UK
32.1) [18–22]. With the exception of the UK, limited
microbiome research, in particular CRC-microbiome
profiling, has been conducted in these countries [6, 23,
24] We sought to address these current limitations by
assessing whether gFOBT cards collected both in the
country of interest and from UK volunteers, then
stored/transported at ambient temperatures, could assess
CRC-associated microbes comparably around the globe.
After establishing the efficacy of our methodology, we
compared the faecal microbiomes of ten CRC patients
and ten non-CRC controls each from India, Vietnam,
Chile, and Argentina, using a standardised methodology
to mitigate technical biases, and found the resulting
CRC-associated amplicon profiles to be comparable with




Replicate gFOBT samples were created to investigate the
effect of international transport and storage (Fig. 1a). A
convenience group of five healthy UK volunteers (rela-
tives of a member of the UK research team) was used;
each volunteer donated a stool. Volunteers were aged
between 28 and 66, had no history of colonoscopy or
antibiotic use within the preceding 6 months, and had
no comorbidities. Each stool was used to make ten
gFOBT (Hema Screen, Immunostics, Inc). gFOBT were
stored at room temperature for 24 h. Developer solution
(Hema Screen, Immunostics, Inc) was then applied and
gFOBT were left to dry. gFOBT were stored in individ-
ual sealed bags at room temperature prior to transit
(115–171 days).
Two gFOBT from each volunteer remained within the
UK; these acted as baseline samples. Two gFOBT from
each volunteer were transported at ambient temperature
to India, Vietnam, Chile, and Argentina (transit time 4–
8 days). Of these, one from each volunteer was stored at
room temperature for a short period (2–11 days,
dependent upon courier collection) before being
returned to the UK (transit time 3–6 days). gFOBT were
transported at ambient temperature, except for the
gFOBT from Argentina which were received with ice
packs due to a mistake by the courier. To limit batch ef-
fects, DNA extraction was performed upon receipt of
samples from all four countries, and DNA extraction of
samples which had remained in the UK was performed
at the same time.
To assess the effect of the storage conditions which
the CRC/non-CRC control samples had been subject to,
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a second set of gFOBT was stored in India, Vietnam,
Chile, and Argentina at room temperature for the dur-
ation of CRC/non-CRC control sample collection
(Vietnam 29 days, Argentina 76 days, India 115 days, and
Chile 196 days). The recorded laboratory temperatures
were as follows: UK (mean monthly temperature 20–
23 °C, maximum 27 °C), Vietnam (mean not available,
maximum 25 °C), Argentina (mean 15 °C, maximum
20 °C), Chile (mean 20 °C, maximum 22 °C), and India
(mean 24 °C, maximum 27 °C). Samples were returned at
ambient temperature with the CRC/non-CRC control
samples (transit time 5–10 days), and DNA extraction
was performed upon receipt.
CRC and non-CRC control samples
gFOBT and clinical data were collected from ten CRC pa-
tients and ten non-CRC controls each from Vietnam (Can
Tho University of Medicine and Pharmacy, Can Tho,
April–June 2018), Argentina (Hospital Italiano de Buenos
Aires, June–August 2018), India (Cancer Institute (WIA)
Chennai, July–October 2018), and Chile (Universidad de
los Andes Santiago, October 2018–February 2019, sam-
ples collected in fact from 11 CRC patients and ten non-
CRC controls), to give a total cohort of 81 individuals (Fig.
1a). Non-CRC controls comprised either people with a
normal bowel at colonoscopy (Vietnam and Argentina) or
asymptomatic individuals working in the affiliated Univer-
sity (Chile and India). Both control groups (colonoscopy-
normal controls or asymptomatic controls) are variously
used in microbiome studies; we offered flexibility as the
institutes in Chile and India had limited access to
colonoscopy-normal controls (colonoscopy is less readily
available in some developing countries). Colonoscopies
were carried out a minimum of 2 weeks prior to sample
collection (during which time the majority of taxa return
to baseline). CRC patients were treatment-naïve. Study
participants were aged over 18. Exclusion criteria included
the following: antibiotic use within the preceding
6 months; foreign travel within the preceding 2 weeks; col-
onoscopy within the preceding 2 weeks; related to another
Fig. 1 Study overview. International transport and storage has no appreciable effect on the microbiome profile of UK volunteer samples. a Study
overview (AR = Argentina; CH = Chile; IN = India; VI = Vietnam; EMP = Earth Microbiome Project; PCoA = principle coordinate analysis). b PCoA of Bray-
Curtis distances between UK volunteer samples. As expected, the vast majority of microbiome variation is driven by baseline inter-individual differences
independently of storage location. c Distribution of Bray-Curtis distances between UK volunteer samples. From top to bottom: between individuals
within each country of storage (Argentina, Chile, India, UK, Vietnam); within individual for samples stored in Argentina, Chile, India, or Vietnam for the
duration of CRC/non-CRC control sample collection; within individual for samples stored in Argentina, Chile, India, or Vietnam for ~ 48 h; within individual
for samples that remained in the UK. Again, differences due to storage are small relative to inter-individual differences
Young et al. Genome Medicine           (2021) 13:27 Page 3 of 13
study participant; colostomy; history of previous CRC/ad-
enoma, colorectal surgery, pelvic radiation, or chemother-
apy; known CRC syndrome or family history of hereditary
CRC; and coexistent IBD or infectious bowel disease.
To limit batch effects, samples from CRC patients and
non-CRC controls were collected as far as possible alter-
nately and were transported and processed as a single
batch. Participants provided a stool which was used to
prepare a gFOBT. Developer solution was applied the
same day in the majority of instances (occasionally the
following day), and gFOBT were left to dry. gFOBT were
stored in individual sealed bags at room temperature.
Once collection was complete, samples were returned to
the UK at ambient temperature.
DNA extraction replicate samples
To assess the effect of prolonged UK storage at room
temperature, DNA extraction replicates were created
from a subset of the CRC/non-CRC control samples
(n = 21 pairs), by extracting DNA from three squares of
faecally loaded card at baseline (details below) and sub-
sequently from the three remaining squares after pro-
longed UK storage (Fig. 1a). Time between DNA
extraction of replicate pairs was as follows: Chilean sam-
ples 27 days, Indian samples 140 days, Argentinian sam-
ples 211 days, and Vietnamese samples 252 days.
DNA extraction
Sample processing was performed at the University of
Leeds. The QIAamp DNA Stool Mini Kit (Qiagen,
Germany) was used until its discontinuation in August
2018, whereupon the equivalent QIAamp DNA Mini Kit
(Qiagen, Germany) and Buffer ASL (Qiagen, Germany)
were used.
From each gFOBT, three squares of faecally loaded
card were dissected and processed as a single combined
sample. The rationale of this approach is that it subsam-
ples a larger volume of stool, ensuring adequate biomass
even from thinly smeared gFOBT (the volume of stool
per gFOBT can be very variable when prepared by study
participants), and leaves three squares remaining for al-
ternative analysis or DNA extraction replicates. Next,
800 μl of Buffer ASL was added and samples were incu-
bated at 23 °C on a Thermomixer Comfort (Eppendorf
UK) at 850 rpm for 1 h. Samples were briefly centrifuged
and supernatant transferred to pathogen lysis tubes (S)
(Qiagen, Germany). Samples were agitated (Vibrax VXR,
IKA, UK) at a motor setting of 1800–2200 for 10 min
followed by incubation at 95 °C on the Thermomixer at
850 rpm for 15min. Samples were then centrifuged at
18625g for 1 min, and supernatant was transferred to a
tube containing 173 μl of 10M ammonium acetate. We
then vortexed the samples and placed them on ice for
5 min, then centrifuged at 18625g for 5 min.
Supernatant was transferred to a tube containing 725 μl
of propan-2-ol, vortexed, and placed on ice for 30 min.
Then, samples were centrifuged at 18625g for 10 min,
supernatant was discarded, and 1ml of 70% ethanol was
added. Samples were centrifuged at 18625g for 5 min,
supernatant discarded, and 500 μl 70% ethanol was
added. Samples were centrifuged at 18625g for 3 min,
supernatant discarded, and the samples left for 10 min
to evaporate residual ethanol. Two hundred microliters
of tris-EDTA was added, and after 10 min, samples were
vortexed and added to tubes containing 200 μl of Buffer
AL (QIAamp DNA Mini Kit). Fifteen microliters of Pro-
teinase K (QIAamp DNA Mini Kit) was added; the sam-
ples were vortexed and incubated at 70 °C on the
Thermomixer at 650 rpm for 10 min. The QIAamp
DNA Mini Kit protocol was then followed. To elute
DNA, 100 μl of UV-irradiated molecular biology grade
water was added to samples for 5 min before centrifu-
ging at 18625g for 1 min.
16S rRNA library preparation and NGS
The Earth Microbiome Project (EMP) 16S Illumina
Amplicon library preparation methodology was followed
[25], with Illumina 16S V4 primer constructs 515F
(Parada)-806R (Apprill) [26, 27]. Single (rather than trip-
licate) PCR reactions were performed per sample, each
with a starting amount of 20 ng DNA. One hundred
fifty-two samples were sequenced as part of a total pool
of 996 samples from other projects, on one lane of an
Illumina HiSeq 3000, for 2x150bp sequencing, with a 10
bp index read.
Bioinformatic processing and statistical analysis
Reads were stripped of adaptors using cutadapt [28].
Further processing was carried out in QIIME2 (version
2019.4) [29]. Reads were trimmed to a maximum of 145
bp, pairs merged, denoised, and representative sequences
chosen using DADA2 [30].
Taxa were assigned to representative sequences by the
QIIME2 feature classifier using the BLAST+ algorithm
[31, 32], aligning sequences against the SILVA version
132 99% similarity database [33].
Within the QIIME2 environment, samples were rari-
fied to the depth of the sample with fewest QC-passed
sequences (51,000), and Shannon index alpha diversity
was calculated [34], with significance assessed by the
Kruskal-Wallis test [35]. Rarified samples were used to
calculate Bray-Curtis beta diversity [36], and principle
coordinate analysis (PCoA) was performed. Taxa, repre-
sentative sequences, and distance matrices were
exported from QIIME2 for analysis and graphical repre-
sentation using R (version 3.5.1).
Significance of differences in beta diversity between
groups was assessed by PERMANOVA analysis of Bray-
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Curtis distances performed using the adonis function
within vegan [37]. Where necessary, multivariate models
were built using repeated measures aware permutations
within the PERMANOVA test, to account for repeated
measures per individual (https://bitbucket.org/biobakery/
hmp2_analysis/src/default/overview/src/omnibus_tests.r)
[38]. Network analysis of genus level Bray-Curtis distances
was performed using phyloseq [39].
To investigate the discriminatory performance of the
microbiome, a random forest (RF) model [40] was built
using the combined cohort, using the packages random-
Forest [41] and pROC [42]. To adjust for the effects of
age, after per-sample normalisation, a linear model of each
taxon with age was calculated, and the residual values ra-
ther than taxon abundance used to construct a RF model.
Taxa from the combined cohort were compared to
other CRC faecal metagenomic datasets [23, 43–45], proc-
essed using MetaPhlAn version 3.0 [46]. The datasets con-
tain samples from the following countries: Feng – Austria
(n = 107); Gupta – India (n = 60); Thomas_a and Thomas_
b – Italy (n = 106); Vogtmann – USA (n = 104); Wirbel –
Germany (n = 125); Yachida – Japan (n = 518); Yu – Hong
Kong, China (n = 128); and Zeller – France (n = 114). All
datasets were collapsed to genus level for comparison with
16S rRNA gene amplicon data. The Thomas_c [44] data-
set was merged with the Yachida [45] dataset, as both
originated from the same cohort. A random forest (RF)
model [40] was built from each dataset using the random-
Forest [41] and compared with every other dataset using
pROC [42]. Area under the curve (AUC) for each valid-
ation was recorded, as were taxa importance ranks for
each model. For self-vs-self comparisons, each study was
randomly split into equal sized training and validation sets
20 times, and mean AUC recorded. Additionally, a leave-
one-dataset-out (LODO) comparison was performed,
whereby models were built from all but one dataset, and
validated on the missing dataset. Finally, taxa differing sig-
nificantly between groups were obtained using LEfSe (Lin-
ear discriminant analysis Effect Size) [47].
Mann-Whitney and Fisher’s exact test were performed to
assess intra-country demographic differences; hypotheses
were two-tailed with a significance level of 0.05. Kruskal-
Wallis ANOVA was performed to assess inter-country differ-
ences of tumour size, and post-hoc Dunn p values with
Benjamini-Hochberg FDR adjustment were calculated.
The dataset supporting the conclusions of this article
is available in the ENA repository [48]: https://www.ebi.
ac.uk/ena/data/view/PRJEB36789
Results
CRC and non-CRC control populations and gFOBT-based
microbiome profiling strategies
In total, we profiled 16S rRNA gene amplicons from
stool representing the gut microbiomes of 41 CRC
participants and 40 non-CRC controls, spanning
Argentina, Chile, India, and Vietnam (Fig. 1, Table 1).
The majority of tumours were located in the caecum/as-
cending colon or sigmoid/rectum and were stage pT3 or
pT4 (Table 2).
Age is, of course, a substantial contributor to CRC de-
velopment, although it is not generally a major driver of
microbiome variation within the range studied here (e.g.
associated with ~ 5% of taxonomic variation, see below).
The median age of non-CRC controls from Argentina,
Chile, and India was substantially younger than the cor-
responding CRC patients, and the median age of CRC
patients from India and Vietnam was younger than that
of CRC patients from Chile and Argentina (Table 1).
While this did not substantially affect subsequent ana-
lyses when tested, we note it both here and in our initial
profiles of microbiome composition below. Non-CRC
controls from Chile and India were asymptomatic indi-
viduals working in the affiliated Universities. Non-CRC
controls from Vietnam and Argentina underwent colon-
oscopy, yielding descriptions of ‘macroscopically normal
bowel’ (n = 14), diverticulosis (n = 4), or ‘macroscopically
normal bowel with haemorrhoids’ (n = 2), which are
grouped together in subsequent analyses as non-CRC
control (it should be noted that these are common col-
onoscopy findings in older populations and have not
been associated with a distinct microbiome profile) [49] .
The total reads/sample (CRC patients, non-CRC con-
trols and UK volunteers) were 51,000–167,000 (median
117,000).
International transport and storage of gFOBT, and
prolonged storage in the UK, has no appreciable effect
on results
To first investigate the effect of international transport
and storage, 50 replicate gFOBT were created using
stool from a subset of the total population, comprising
five UK volunteers (ten replicate gFOBT/volunteer).
Two gFOBT from each volunteer remained in the UK.
Two gFOBT from each volunteer were transported to
institutes in Argentina, Chile, India, and Vietnam; of
these, one from each volunteer was stored for a short
duration, and one was stored for the duration of CRC/
non-CRC control sample collection (Fig. 1a).
Neither country nor duration of storage had a signifi-
cant effect on the microbiome structure of the UK vol-
unteer samples, which as expected grouped by UK
volunteer (Fig. 1b, c, Additional file 1: Fig. S1A). PERM
ANOVA of Bray-Curtis dissimilarity confirmed this,
quantifying the effect of UK volunteer as R2 = 94% (p =
0.001) (Fig. 2b, Additional file 1: Table S1). Each UK vol-
unteer’s taxonomic composition was assessed essentially
equivalently across the different storage methods, and
whilst there was a minor amount of taxonomic
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Table 1 CRC and non-CRC control characteristics
Argentina Chile India Vietnam
CRC NC CRC NC CRC NC CRC NC
Number of participants 10 10 11 10 10 10 10 10
Male 4 6 4 4 7 6 5 3
Median age (range) 81 (61–89) 55.5 (37–72) 70 (56–86) 34 (22–75) 56.5 (33–73) 34 (26–45) 58 (49–88) 58.5 (37–71)
MW p = 4.4 × 10−4 MW p = 3.5 × 10−3 MW p = 1 × 10−3
History of colonoscopya 10 10 11 0 8 0 10 10
FE p < 1 × 10−5 FE p = 7 × 10−4
Medication use 9 6 9 3 6 1 10 10
FE p = 3 × 10−2
Comorbiditiesb 8 4 9 5 7 0 3 3
FE p = 3.1 × 10−3
Current smokerc 0 1 0 3 1 0 3 1
Drinks alcohol 3 4 4 9 1 3 3 2
FE p = 2.4 × 10−2
Vegetarian 0 0 0 0 2 6 0 1
CRC CRC patient, NC non-CRC control
Mann-Whitney (MW) and Fisher’s exact test (FE) were performed to assess intra-country differences; hypotheses were two-tailed with a significance level of 0.05.
Significant differences are in bold and the p value stated
aHistory of colonoscopy indicates whether participants had ever had a colonoscopy with bowel preparation prior to sample collection
bComorbidities included in our population profile, but not as substantial analysis covariates: hypertension, gastric ulcer, gastro-oesophageal reflux disease, insulin
resistance/diabetes, thyroid disease, obesity, and hypercholesterolaemia
cCurrent smoker includes participants who stopped smoking within the preceding month
Table 2 Tumour characteristics
Argentina n = 10 Chile n = 11 India n = 10 Vietnam n = 10
Tumour locationa
Caecum or ascending colon 5 5 2 0
Transverse colon 0 0 0 1
Descending colon 0 0 0 1
Sigmoid colon or rectum 4 6 8 8
Data not available 1 0 0 0
Maximum tumour size in one direction
Median (cm) (range) 4 (0.7–7) 6 (2.5–11) 5 (3–5.5) 4 (3–5)
Data not available 2 0 7 0
Kruskal Wallis ANOVA p = 2.9 × 10−2 Post-hoc Dunn significant pairwise differences (Benjamini-Hochberg FDR adjusted): Chile vs
Vietnam p = 3.5 × 10−2
Tumour stage (TNM8)a
T1 0 2 0 0
T2 1 1 4 0
T3 8 8 4 0
T4 0 0 0 10
Data not available 1 0 2 0
aTumour location and stage have not been tested for heterogeneity due to small numbers
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variability (average inter-individual replicate Bray-
Curtis dissimilarity 0.13), this affected both samples
which remained in the UK and samples which were
transported and stored internationally (Additional file
1: Fig. S1B).
To determine whether the microbiome would remain
stable if samples were stored for a prolonged period at
room temperature in the UK pending DNA extraction,
extraction replicates were created from a subset of the
CRC/non-CRC control samples (Fig. 1a). DNA extrac-
tion was performed upon sample receipt, by dissecting
three squares of faecally loaded card, and extraction rep-
licates were created by dissecting the alternate three
squares after a period of storage at room temperature.
Pairs of replicate samples had similar microbiome struc-
tures and taxonomic profiles (average inter-individual
replicate Bray-Curtis dissimilarity = 0.17) (Additional file
1: Fig. S2A-C). No significant taxonomic differences
were detected by LEfSe between the groups of baseline
and replicate samples.
Geography drives CRC-independent gut microbiome
structure of participants
Aside from inter-individual differences, the greatest de-
terminant of microbiome structure was country of origin
(Fig. 2a). PERMANOVA quantified this based on Bray-
Curtis distances (R2 = 14%) (p = 0.001), with ‘disease sta-
tus’ (CRC or non-CRC control) contributing far less
(R2 = 2%) (p = 0.019) (Fig. 2b, c, Additional file 1: Table
S1). A significant difference in alpha diversity (Shannon)
was likewise detected between countries (Kruskal Wallis
p = 4 × 10−5). Specifically, the alpha diversities of Viet-
namese and Indian samples were significantly lower than
those of the Argentinian and Chilean samples, and those
of the Indian samples were lower than the Vietnamese
(Fig. 2d). No significant difference in Shannon diversity
index was detected between overall CRC and non-CRC
control samples (Kruskal Wallis p = 0.28).
In addition to country of origin, continent was itself a
driver of microbiome structure, with the majority of the
Asian samples (India and Vietnam) distinct from the
Fig. 2 Country and continent drive microbiome structure. a PCoA of Bray-Curtis distances between all samples. b PERMANOVA based on Bray-Curtis
distances between CRC and non-CRC control samples and UK volunteer samples. For the CRC/non-CRC control samples: ‘country of origin’ = Argentina,
Chile, India or Vietnam; ‘disease status’ = CRC or non-CRC control. For the UK volunteer samples: ‘country of storage’ = Argentina, Chile, India, Vietnam or
UK (only samples stored in the UK or short-term outside the UK were used in this analysis, as these samples underwent DNA extraction at the same
time); ‘duration of storage’ = short-term or long-term storage outside the UK (samples which remained in the UK were excluded from this analysis).
**p≤ 0.01. *p≤ 0.05. c Distribution of Bray-Curtis distances for CRC and non-CRC control samples: ‘disease-status group’ = CRC or non-CRC control. d
Shannon diversity indices for CRC and non-CRC control samples. At the taxonomic resolution achievable from the data, Asian individuals generally had
lower diversity than South American individuals. e Network representation of all samples based on Bray-Curtis distances. Each UK volunteer is
represented by a single point, reflecting the average relative abundance across all samples derived from that individual. Overall dissimilarities are driven
by a weak segregation between Asian and South American microbiomes
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majority of the South American samples (Chile and
Argentina) (Fig. 2e). In our study, similar to previous re-
ports, Asian samples had a significantly higher relative
abundance of Prevotella (LDA score 5.173, p = 2.79 ×
10−6) and lower relative abundance of Bacteroides (LDA
score 4.841, p = 2.32 × 10−6) compared with South
American samples (Additional file 1: Fig. S3A-C).
The CRC-associated microbiome of developing countries
resembles that of developed countries
To determine the potential of the microbiome to discrim-
inate between CRC and non-CRC control samples, a RF
model was built using the combined total dataset of CRC
and non-CRC controls (AUC 0.77 (CI 0.67–0.87)). Given
the age-imbalance within our dataset, we compared the
result with an age-adjusted RF model; the age-adjusted RF
model performed equivalently (AUC 0.80 (CI 0.69–0.89)),
confirming that age does not account for the discrimin-
atory performance of the RF model.
Next, the combined total dataset of CRC and non-
CRC control amplicon profiles was compared to CRC
faecal shotgun metagenomic datasets from the existing
literature (Fig. 3) [23, 43–45] . These nine existing stud-
ies included 1262 total samples from the following coun-
tries: France (n = 114), Austria (n = 107), Italy (n = 106),
Germany (n = 125), USA (n = 104), India (n = 60), Hong
Kong, and China (n = 128) and Japan (n = 518). A ran-
dom forest (RF) model trained using the current study’s
amplicon dataset and tested using the external metage-
nomic datasets, paralleling previous methodology [44],
performed strikingly similarly (mean AUC 0.75) to
models trained using the external metagenomes (mean
AUC 0.71–0.80) (Fig. 3a). Similarly, models trained using
the external datasets performed similarly when tested
using the current study’s dataset (mean AUC 0.78, leave-
one-dataset-out AUC 0.85) or the other external datasets
(mean AUC 0.67–0.85, leave-one-dataset-out AUC
0.73–0.91).
RF models built using each dataset ranked CRC-
associated taxa of greatest discriminatory importance
similarly (Fig. 3b, Additional file 1: Fig. S4A). The five
CRC-associated taxa which were of greatest importance
to the majority of the models (Parvimonas, Peptostrepto-
coccus, Fusobacterium, Alistipes, and Escherichia) were
ranked in the top ten taxa by the model built using the
current study’s dataset. The five most important taxa for
the current study’s model were Peptostreptococcus,
Odoribacter, Parvimonas, Porphyromonas, and Alistipes.
As mentioned, Peptostreptococcus, Parvimonas, and
Alistipes were ranked highly by the majority of external
Fig. 3 CRC prediction performance is comparable and taxonomically similar across datasets. a Cross-prediction matrix demonstrating random
forest AUC based on genus-level relative abundances. LODO (leave-one-dataset-out) refers to the AUC generated by training a model using all
but the dataset of the associated column and testing it using the dataset of that column. The datasets contain samples from the following
countries: Feng – Austria; Gupta – India; Thomas_a – Italy; Thomas_b – Italy; Vogtmann – USA; Wirbel – Germany; Yachida – Japan; Yu – Hong
Kong, China; Zeller – France. b The importance of each genus for the cross-validation performance in each dataset using gini values. Only genera
in the top five in at least one dataset are shown
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models. In contrast, Odoribacter and Porphyromonas
were ranked highly by some but not all of the exter-
nal models; this discrepancy could be secondary to
demographic or technical differences between cohorts.
Within the current study, CRC-associated taxa dif-
fered by country; Peptostreptococcus and Parvimonas
were CRC-enriched in cohorts from three of the four
countries (India, Chile and Vietnam) (Additional file
1: Fig. S4B-F).
These results together indicate that the CRC-associated
microbiome is substantially consistent, and can be consist-
ently measured, across multiple very different inter-
national populations. This was true across cohorts and
sample handling within this study and surprisingly also
proved to hold when comparing these diverse populations
to external CRC cohorts. In general, control-associated
taxa were of lesser importance to the RF models than
CRC-associated taxa. This is likely due to the heteroge-
neous nature of the current study’s control group and of
different “healthy” populations’ gut microbiomes gener-
ally. It suggests that the commonality of some CRC-
associated microbiome shifts may be particularly import-
ant, either causally or in response to cancer-induced
changes in the intestinal microenvironment.
Discussion
To date, limited microbiome research has been con-
ducted in developing countries, leaving a gap in our
knowledge of gut microbial relationships with chronic
disease in global populations. We sought to address this
in CRC by establishing a network of researchers and
participants from Argentina, Chile, India, and Vietnam.
First, we demonstrated that gFOBT, stored at room
temperature and, importantly, also transported at ambi-
ent temperature, were suitable for genus-level faecal mi-
crobial taxonomic profiling in a translational setting
across these multinational cohorts. This also remained
true for gFOBT samples with prolonged storage periods
at room temperature in the UK. This allowed us to fur-
ther profile the faecal microbiomes of CRC patients and
non-CRC controls from Argentina, Chile, India, and
Vietnam, and, through comparison with external data-
sets, to demonstrate that the CRC-associated micro-
biome of these developing countries resembles that of
developed countries.
As in previous methodologically similar studies in
European or North American populations, the micro-
biome profile of replicate gFOBT samples from five UK
volunteers that were either stored in the UK, or trans-
ported and stored abroad (maximum temperature 27 °C)
for either a short or long (maximum 196 days) duration,
was predominantly shaped by inter-individual differ-
ences and not appreciably by storage conditions. Simi-
larly, DNA extraction replicate pairs demonstrated
consistent microbiome profiles after UK room
temperature storage (maximum 252 days). Together,
these results indicate that sample analysis did not suffer
due to bacterial overgrowth or DNA degradation, despite
prolonged storage and transportation at ambient
temperature. This is presumably due to the action of
Hema Screen developer solution (which contains a stabi-
lised mixture of hydrogen peroxide (< 6%) and 75% de-
natured ethyl alcohol in aqueous solution); notably,
developer would not normally be added to screening
gFOBT samples immediately upon collection, although a
rapid fixation process is easily applicable in field settings.
Although not formally assessed by this study, it is ex-
pected that an equivalent alcohol/hydrogen-peroxide
based solution could be readily made in-house at low-
cost, facilitating microbiome-research in developing
countries.
Our results agree with and build on existing studies
which have also demonstrated the suitability of gFOBT
for microbial community amplicon profiling, aiming to
validate such methods not only for research but for field
clinical settings [9–15]. Our study adds to the small
number which have assessed stability after prolonged
storage, by demonstrating stability after eight months for
21 replicate pairs. Two studies investigated the micro-
biome of card samples at higher ambient temperatures;
one showed stability of FTA at 4–40 °C [16] and the
other showed stability of gFOBT stored for four days at
ambient temperature in Bangladesh [17]. Our study cor-
roborates these findings; additionally, we show that pro-
longed storage at room temperature in developing
countries and international transport of samples at am-
bient temperature has no detrimental effect. The latter
in particular is an important finding, offering an alterna-
tive to fresh and/or frozen samples that is practical for
use at population scale in international clinical settings
at reduced cost. While the types and detail of micro-
biome profiles that can be obtained from such samples
remains limited, it is conversely appropriate for some
important population-scale applications such as cancer
biomarker testing. We hope these findings will thus en-
courage others to consider using gFOBT for appropriate
epidemiology in settings where more detailed sample
types are infeasible.
As expected, we found that for the CRC and non-CRC
control samples, the greatest determinant of microbiome
structure, aside from inter-individual variation, was
country of origin, corresponding to 14% of overall mi-
crobial variation. This is in agreement with a previous
study, in which country of origin accounted for a similar
amount of variation (R2 = 22%) [50]. Additionally, coun-
tries within continents also showed greater microbial
similarity [51, 52]. Inter-continent differences in micro-
biome structure were likely a consequence of the inverse
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Prevotella to Bacteroides ratio of Asian and South
American samples. Similar results have been previously
documented by microbiome studies of healthy Indians,
Argentinians, and Chileans and are in keeping with ex-
pected differences between these countries [52–58]. The
fact that the Asian samples had lower alpha diversities
was somewhat surprising. However, other studies have
also demonstrated low alpha diversity of faecal samples
from healthy Indians, perhaps due to the high relative
abundance of Prevotella [54, 56], as clades such as these
and Bacteroides can be difficult to distinguish in
amplicon-based profiling (thus leading to lower apparent
diversity when dominant).
By comparing a random forest model built from our
dataset with models built using external, largely devel-
oped cohorts, we demonstrated a surprising commonal-
ity of the CRC-associated microbiome, particularly CRC-
associated taxa, between developed and developing pop-
ulations. This finding is remarkable in light of technical
differences between the studies (method of sample col-
lection and amplicon versus metagenomic sequencing,
to name the largest) and the fact that we combined CRC
patients and non-CRC controls from four developing
countries with distinct microbiome profiles. It should be
noted, however, that whilst the direction of the effect is
similar between our study and larger, more homoge-
neous, later-stage CRC cohorts, the magnitude of the ef-
fect is understandably smaller. The five taxa which were
of greatest importance to the majority of these models
were Parvimonas, Peptostreptococcus, Fusobacterium,
Alistipes, and Escherichia. Although we were limited in
the precision with which we could measure them, within
these genera previous studies have associated several of
their species with CRC: Peptostreptococcus stomatis [23],
Peptostreptococcus anaerobius [45], Fusobacterium
nucleatum [59], Parvimonas micra [59], Alistipes finegol-
dii [59], and pks+ Escherichia coli [2]. Of these, Fusobac-
terium nucleatum and pks+ Escherichia coli in particular
have been suggested as putative ‘oncomicrobes’. Fuso-
bacterium nucleatum has been shown to promote
tumour proliferation, pro-tumour inflammation and to
subvert anti-tumour immune responses [60], whilst coli-
bactin, produced by pks+ Escherichia coli, has been
shown to cause DNA damage [2].
Outside of these examples, many of the additional
CRC-enriched taxa are oral bacteria that rarely colonise
the gut during ‘health’ but have been implicated in a var-
iety of inflammatory and dysbiotic conditions [61]. It has
been hypothesised that oral microbial growth in the
colon can cause increased mucosal permeability, with
subsequent bacterial invasion, inflammation, and epithe-
lial proliferation, and indeed associated biofilms have
been shown to induce tumourigenesis in a mouse model
[62–64]. Whether cause or consequence of tumour
formation, the fact that these bacteria are found in both
developed and developing cohorts points towards the
oral microbiome as a shared source of CRC-associated
taxa. Geographical differences of the oral microbiome
have been described, but the universality of CRC-
associated taxa derived from the oral microbiome has
not, to our knowledge, been extensively investigated
[65].
Continuing to explore the global effects of the micro-
biome on CRC has the potential to improve both the
disease’s management worldwide and our understanding
of the underlying basic biology. It will be important to
expand the cohort by sampling a larger number of par-
ticipants with more rigorous age and gender matching,
in addition to expanding the number of countries pro-
filed, as well as the geographical catchment within coun-
tries, many of which show great intra-country diversity.
Importantly, microbiome profiling may provide valuable
insight into the rising incidence of CRC within these
countries, and the shared CRC-associated microbiome
raises the potential of a generalisable microbiome-based
CRC screening test. To this end, we have demonstrated
that gFOBT is a suitable method of faecal sample collec-
tion for 16S rRNA gene research in developing countries
(Argentina, Chile, India, and Vietnam) and that their
CRC-associated microbiome shares many features with
that of developed countries. We encourage other re-
searchers to investigate the CRC microbiome in greater
depth and in additional populations, with the goal of
preventing or treating the disease around the globe.
Conclusions
Limited CRC-microbiome research has been conducted
in developing countries, yet CRC incidence is increasing
in these areas. One of the impediments to creating and
applying CRC-microbiome biomarkers is the collection
of frozen stool samples. Here, we investigated the effi-
cacy of stool-based biomarkers using bowel cancer
screening cards (gFOBT), stored and, importantly, trans-
ported at room temperature. We then used this tech-
nique to investigate the microbiome of CRC patients
and controls from four developing countries (Argentina,
Chile, India, and Vietnam). Remarkably, we show that
the CRC-associated microbiome of these developing
countries resembles that of developed countries, even
when using limited, field-appropriate, and scalable sam-
pling methods.
Supplementary Information
The online version contains supplementary material available at https://doi.
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Additional file 1: Table S1. PERMANOVA analysis. P-values < 0.05 are
shaded grey. R2 values are recorded to two decimal places. Fig. S1A.
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Distribution of Bray-Curtis distances between UK volunteer samples. The
five UK volunteers are labelled A1-E5. Within individual Bray-Curtis dis-
tances are low, despite differences in sample storage. Fig. S1B. Genus-
level taxonomic profile of UK volunteer samples. Each bar represents a
sample labelled as: UK volunteer (A1-E5); country of storage (AR =
Argentina; CH = Chile; IN = India; VI = Vietnam; UK); storage duration (S =
short-term storage; L = long-term storage (i.e. the duration of CRC/non-
CRC control sample collection); R = samples which remained in the UK).
The key contains the top 20 taxa (where a genus was described as famil-
y_group, groups were merged and only the family name is included for
brevity); additional taxa are coloured grey. There is minimal taxonomic
variability between samples from the same individual, and taxonomic
variability affects both samples which remained in the UK and samples
which were transported and stored internationally. Fig. S2A. PCoA of
Bray-Curtis distances for extraction replicates. Points are coloured as ex-
traction replicate pairs. Fig. S2B. Distribution of Bray-Curtis distances be-
tween extraction replicate samples. Fig. S2C. Genus-level taxonomic
profile of extraction replicate samples. Each bar represents a sample la-
belled as follows: country of origin (AR = Argentina; CH = Chile; IN = India;
VI = Vietnam); disease status (CRC = CRC; NC = non-CRC control); sample
ID; whether the sample is an extraction replicate (indicated by .R). For
ease of comparison, taxa are coloured as per Supplementary Fig. 1B. Rep-
licate pairs have similar taxonomic profiles. Fig. S3A. Genus-level taxo-
nomic profile of CRC and non-CRC control samples. Each bar represents a
sample labelled as follows: country of origin (AR = Argentina; CH = Chile;
IN = India; VI = Vietnam); disease status (CRC = CRC; NC = non-CRC con-
trol). For ease of comparison, taxa are coloured as per Supplementary
Fig. 1B. South American samples generally have a high relative abun-
dance of Bacteroides, and Asian samples a high relative abundance of Pre-
votella. Fig. S3B. The mean taxonomic composition (genus-level) of CRC
and non-CRC control samples. Each bar represents the mean taxonomic
composition of a group labelled as follows: country of origin (AR =
Argentina; CH = Chile; IN = India; VI = Vietnam); disease status (CRC = CRC;
NC = non-CRC control). For ease of comparison, taxa are coloured as per
Supplementary Fig. 1B. South American samples have a high relative
abundance of Bacteroides, and Asian samples a high relative abundance
of Prevotella. Fig. S3C. LEfSe plot illustrating taxa enriched in South
American (SA) compared with Asian (AS) samples. Fig. S4A. Distributions
of relative abundance of genera of greatest importance to random forest
models. The boxplots labelled ‘All’ are a summary of all of the studies, in-
cluding the current study. The first 19 taxa are CRC-enriched (mean rela-
tive abundance) in the majority of studies; the final 5 taxa are control-
enriched (mean relative abundance) in the majority of studies. Fig. S4B.
LEfSe plot illustrating taxa enriched in CRC compared with non-CRC con-
trols for the current study cohort as a whole. Fig. S4C. LEfSe plot illus-
trating taxa enriched in CRC compared with non-CRC controls
(Argentina). Fig. S4D. LEfSe plot illustrating taxa enriched in CRC com-
pared with non-CRC controls (Chile). Fig. S4E. LEfSe plot illustrating taxa
enriched in CRC compared with non-CRC controls (India). Fig. S4F. LEfSe
plot illustrating taxa enriched in CRC compared with non-CRC controls
(Vietnam).
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